Skinvisible (SKVI) EBIT Growth (1y) (2011 - 2026)
Powered by 
Analysis
Skinvisible (SKVI) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 7.43% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 31.43% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -111.70% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -2.34% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -15.58% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -27.06% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 31.60% |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | -9.25% |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | 17.19% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.19% |
| Mar 31, 2026 | 9.95% |
| Dec 31, 2025 | 42.55% |
| Sep 30, 2025 | 15.13% |
| Jun 30, 2025 | 4.52% |
| Mar 31, 2025 | -13.53% |
| Dec 31, 2024 | -45.56% |
| Sep 30, 2024 | -10.48% |
| Jun 30, 2024 | -26.48% |
| Mar 31, 2024 | 3.69% |
| Dec 31, 2023 | -15.99% |
| Sep 30, 2023 | 11.05% |
| Jun 30, 2023 | -231.20% |
| Mar 31, 2023 | -60.81% |
| Dec 31, 2022 | -179.79% |
| Sep 30, 2022 | -1,519.34% |
| Jun 30, 2022 | -46.09% |
| Mar 31, 2022 | 28.43% |
| Dec 31, 2021 | 1,813.37% |
| Sep 30, 2021 | 93.38% |